CXR Biosciences Validates Impact of INGENUITY’s IPA 5.0

CXR Biosciences Validates the Impact of INGENUITY’s IPA 5.0.

Redwood City, CA –MARCH 27th, 2007– Ingenuity Systems, the leading provider of information solutions for the exploration, interpretation, and analysis of experimental data for life sciences researchers, today launched IPA-Tox™, a pathways-driven molecular toxicology solution, that enables researchers to understand safety issues associated with new drug candidates.

Fully integrated within IPA 5.0, IPA-Tox™ provides user-friendly software tools that rapidly assess the toxicity and safety of compounds as well as new chemical content containing thousands of additional drugs and clinical candidates. Ingenuity Pathways Analysis 5.0 (IPA) is a software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research.  IPA is deployed in all major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all experimental platforms, and is used at all stages of the drug discovery and development process, from target identification and validation to identification of biomarkers, predictive toxicology, and pharmacogenomics.
“We use IPA 5.0 in conjunction with targeted laser microdissection microarray analysis for high resolution mechanistic hypothesis generation, to determine human hazard assessment from results in test species” said Dr Ken Brown, Head of Molecular Biology, CXR Biosciences. “Overlaying results from IPA with statistical clustering of microarray data provides new insights into the mechanisms of toxicological responses such as oxidative stress response, interactions of drugs with individual enzymes such as P450’s, and xenobiotic metabolism. This is extremely useful for discovering biomarkers, determining toxicity in humans, and evaluating the utility of new toxicological models for risk assessment”.

New Molecular Toxicity Solution

IPA-Tox™ within IPA 5.0 is designed to:

–          Assess the toxicity and safety of compounds of interest early in the development process. –          Provide expert molecular toxicology data interpretation to non-expert users.
–          Reveal clinical pathology endpoints associated with a dataset.
–          Generate new hypotheses that may not have been revealed using traditional toxicology approaches.
–          Elucidate mechanism of toxicity and identify potential markers of toxicity.
–          Easily access important findings from the scientific literature, including information associated with cardiovascular toxicity, nephrotoxicity, and hepatotoxicity.

“We have listened to our customers and have incorporated their feedback regarding specific features and content to create IPA 5.0,” commented Ramon Felciano, Chief Technology Officer of Ingenuity Systems. “By maintaining an open dialogue with the research community, we are able to deliver software that meets the needs of both biologists and bioinformaticians. To date, IPA has been cited in more than 300 published research papers, and it is now used by every major pharmaceutical company in the world. We see this progress as a validation of our value to researchers in the R&D process.” In addition to the new IPA-Tox™ solution, IPA 5.0 also contains significant enhancements in capabilities in several other areas critical for life science research:
–          The IPA-biomarker™ solution enables researchers to identify, understand, and prioritize biomarker candidates across different stages of drug discovery
–          New capabilities for biological interpretation of experimental data include the ability to easily upload experimental data from multiple sources, send interactive networks and pathway diagrams to colleagues, and create pathway diagrams for publication and presentation Ingenuity Pathway Analysis 5.0 will be broadly available to users in April 2007.

Trials of Ingenuity Pathways Analysis are being offered at For more information about Ingenuity Pathways Analysis 5.0, please email

About CXR Biosciences

CXR Biosciences is a solutions provider developing and applying new models and approaches for drug discovery and the assessment of risks to humans of chemicals. CXR applies a combination of extensive experience in pre-clinical development and risk assessment, together with the application of proprietary post-genomic models for the evaluation of drug metabolism and toxicity. CXR works with over 50 customers and collaborators, including major pharmaceutical companies, industrial chemical companies and small drug discovery companies. CXR Biosciences Ltd. is located in Dundee, Scotland.
About Ingenuity Systems®

Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. Contact:

Holli Dickson

Account Supervisor Porter Novelli Life Sciences 619.849.5380

Heidi Bullock Director, Marketing Ingenuity Systems 650.381.5150
Mike Piper

Senior Business Development Manager CXR Biosciences +44 1382 432 163